NIOX Group (LON:NIOX) Stock Price Down 3.3% – Should You Sell?

NIOX Group Plc (LON:NIOX) dropped 3.3% during mid-day trading on Tuesday . The stock traded as low as GBX 69.40 ($0.93) and last traded at GBX 69.60 ($0.93). Approximately 604,782 shares were traded during trading, a decline of 43% from the average daily volume of 1,053,004 shares. The stock had previously closed at GBX 72 ($0.96).

NIOX Group Stock Performance

The company has a fifty day moving average of GBX 72.30 and a two-hundred day moving average of GBX 68.66. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.94 and a current ratio of 6.31. The company has a market cap of £300.87 million, a price-to-earnings ratio of 57.60 and a beta of 0.92.

NIOX Group (LON:NIOX) last announced its earnings results on Tuesday, September 30th. The company reported GBX 1.43 earnings per share (EPS) for the quarter. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%. Equities research analysts anticipate that NIOX Group Plc will post 1.1658256 EPS for the current year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.